About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« What's ENCODE'd in Your Genome Isn't A Simple Collection of Genes | Main | The Effect of Foreign Generics on the U.S. Drug Supply - Part I »

June 19, 2007

NimbleGen Systems Acquired by Roche

    By Christopher P. Singer --

Roche In a June 19, 2007 press release, NimbleGen Systems Inc. announced that it and Roche have entered into a definitive acquisition agreement.  Under terms of the agreement Roche will pay $272.5 million to NimbleGen stockholders, and NimbleGen will become an integrated part of Roche Applied Science, a group that falls under its Diagnostics Division.  The deal is expected to close in the third quarter of 2007, pending regulatory clearance and the approval of NimbleGen shareholders.

Nimblegen NimbleGen's technology is focused in the area of high density DNA microarrays, which it manufactures using the company's proprietary photochemical process technology, "Maskless Array Synthesis."  The acquisition enables Roche to add a complementary piece to genomic research tools, which currently include the LightCycler qPCR systems and high throughput Sequencing Systems from recently-acquired 454 Life Sciences.

More information regarding the acquisition can be found in Roche's press release.

Posted at 10:33 PM in Licensing |

Comments

The comments to this entry are closed.

January 2025

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

Categories

Archives

More...